A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature

被引:1
作者
Patel, Sandipkumar H. [1 ]
Saito, Yoshihito David [4 ]
Li, Zaibo [3 ]
Ramaswamy, Bhuvaneswari [1 ,2 ]
Stiff, Andrew [2 ]
Kassem, Mahmoud [1 ]
Wesolowski, Robert [1 ,2 ]
机构
[1] Ohio State Univ, Div Med Oncol, Wexner Med Ctr, 1310D Lincoln Tower,1800 Cannon Dr, Columbus, OH 43210 USA
[2] Ohio State Univ, Comprehens Canc Ctr, 410 12th Ave, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pathol, 410 10th AveN337B Doan Hall, Columbus, OH 43210 USA
[4] Sullivan Care Ctr, Queens Med Ctr, West Oahu Queens Canc Ctr, 91-2127 Ft Weaver Rd, Ewa Beach, HI 96706 USA
关键词
Breast cancer; Brain metastases; Chemotherapy; HER2; Hormone receptors; NERVOUS-SYSTEM METASTASES; PROGESTERONE; TRASTUZUMAB; ESTROGEN; THERAPY; 1ST;
D O I
10.1186/s13256-020-02615-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Breast cancer is one of the most common causes of brain metastases. However, the presence of isolated central nervous system (CNS) metastatic disease early in the course of disease relapse is a rare event in cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. Case presentation We summarize the clinical course of a pre-menopausal, 39-year old Caucasian female with history of operable, hormone receptor positive, HER2 negative breast cancer who was initially treated with curative-intend therapy but who unfortunately developed solitary metastatic lesion in the left thalamus. A biopsy of the lesion confirmed the presence of hormone receptor positive, HER2 negative metastatic breast cancer. Patient's CNS metastases continued to progress without any evidence of metastatic disease outside of the central nervous system and she eventually passed away about 5 years after the date of her initial diagnosis and 18 months following the diagnosis with brain metastasis. Conclusion Based on our case, although rare, patients with treated, operable, hormone receptor positive, HER2 negative breast cancer can present with solitary brain metastasis as the only sign of disease recurrence.
引用
收藏
页数:6
相关论文
共 23 条
  • [11] Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
    Lindstrom, Linda Sofie
    Karlsson, Eva
    Wilking, Ulla M.
    Johansson, Ulla
    Hartman, Johan
    Lidbrink, Elisabet Kerstin
    Hatschek, Thomas
    Skoog, Lambert
    Bergh, Jonas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2601 - 2608
  • [12] Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study
    Linot, B.
    Campone, M.
    Augereau, P.
    Delva, R.
    Abadie-Lacourtoisie, S.
    Nebout-Mesgouez, N.
    Capitain, O.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (02) : 253 - 259
  • [13] Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
    Minniti, Giuseppe
    Anzellini, Dimitri
    Reverberi, Chiara
    Cappellini, Gian Carlo Antonini
    Marchetti, Luca
    Bianciardi, Federico
    Bozzao, Alessandro
    Osti, Mattia
    Gentile, Pier Carlo
    Esposito, Vincenzo
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [14] Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
    Murthy, Rashmi
    Borges, Virginia F.
    Conlin, Alison
    Chaves, Jorge
    Chamberlain, Marc
    Gray, Todd
    Vo, Alex
    Hamilton, Erika
    [J]. LANCET ONCOLOGY, 2018, 19 (07) : 880 - 888
  • [15] Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment
    Niwinska, Anna
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2016, 33 (07) : 677 - 685
  • [16] Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
    Olson, E. M.
    Abdel-Rasoul, M.
    Maly, J.
    Wu, C. S.
    Lin, N. U.
    Shapiro, C. L.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (06) : 1526 - 1533
  • [17] CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
    Pestalozzi, Bernhard C.
    Holmes, Eileen
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Hogge, Laurence
    Scullion, Matt
    Lang, Istvan
    Wardley, Andrew
    Lichinitser, Mikhail
    Lopez Sanchez, Roberto I.
    Mueller, Volkmar
    Dodwell, David
    Gelber, Richard D.
    Piccart-Gebhart, Martine J.
    Cameron, David
    [J]. LANCET ONCOLOGY, 2013, 14 (03) : 244 - 248
  • [18] Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer
    Sari, Ebru
    Guler, Gulnur
    Hayran, Mutlu
    Gullu, Ibrahim
    Altundag, Kadri
    Ozisik, Yavuz
    [J]. MEDICAL ONCOLOGY, 2011, 28 (01) : 57 - 63
  • [19] Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis
    Shen, Qi
    Sahin, Aysegul A.
    Hess, Kenneth R.
    Suki, Dima
    Aldape, Kenneth D.
    Sawaya, Raymond
    Ibrahim, Nuhad K.
    [J]. ONCOLOGIST, 2015, 20 (05) : 466 - 473
  • [20] Subtypes of breast cancer show preferential site of relapse
    Smid, Marcel
    Wang, Yixin
    Zhang, Yi
    Sieuwerts, Anieta M.
    Yu, Jack
    Klijn, Jan G. M.
    Foekens, John A.
    Martens, John W. M.
    [J]. CANCER RESEARCH, 2008, 68 (09) : 3108 - 3114